FDA antibiotic approval

Commercializing Antimicrobial Products in the US Market

by
Commercializing antimicrobial products in the US pharmaceutical market and regulatory landscape

Commercializing antimicrobial products in the United States presents a complex intersection of scientific innovation, regulatory scrutiny, and market dynamics. Rising antimicrobial resistance has intensified the urgency for new treatments, yet developers must navigate challenging economic incentives and evolving regulatory frameworks before bringing products to market. Pharmaceutical companies, emerging biotech firms, and academic innovators are increasingly … Read more

Biotech Startups Focused on Antimicrobial Innovation

by
Biotech startups focused on antimicrobial innovation in US drug development laboratory

Biotech startups focused on antimicrobial innovation are redefining how the United States addresses one of the most pressing public health and economic threats of this decade, antimicrobial resistance. As resistant pathogens outpace traditional drug development models, early-stage biotechnology companies are stepping into a space long vacated by large pharmaceutical firms due to weak return profiles … Read more